Malignant hyperthermia must be treated rapidly to avoid fatality, and despite its rarity, healthcare facilities that use known triggering agents must be fully prepared to treat it.
While these products are generally safe when used according to labeling, pharmacists must be familiar with available evidence in order to help patients safely self-medicate.
Scientists from the University of Eastern Finland have identified alterations occurring in the human brain that signal the early stages of this common neurogenerative disease.